Related Experiment Video
Updated: Aug 5, 2026

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice
Published on: April 10, 2026
Modulation of pancreatic β-cell function by adaptogens: Emerging evidence and integrative therapeutic potential
Jeshua Johayra Garcia-Soberanes1, José Fernando Díaz-Villanueva1, Jesus Emanuel Maldonado-Arvizu2
1Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico; Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico.
Abstract:
Pancreatic β-cells are vulnerable to glucotoxicity, lipotoxicity, oxidative and endoplasmic reticulum stress, chronic inflammation, sustained secretory demand, and loss of cellular identity. This narrative review critically evaluates the mechanistic, preclinical, and translational evidence for Panax ginseng, Curcuma longa, Withania somnifera, and Rhodiola rosea as modulators of β-cell function. A focused search of PubMed, Scopus, Web of Science, and Google Scholar prioritized studies that used β-cell lines, isolated islets, pancreatic tissue, and diabetic animal models, and that reported clinical outcomes related to glycemic control and β-cell function. The available evidence remains predominantly preclinical. Ginseng provides pancreas-level evidence for islet preservation and endocrine-cell remodeling; curcumin shows the strongest evidence for pancreatic and isolated-islet cytoprotection, although its translational relevance is limited by poor and formulation-dependent bioavailability. In a 9-month trial, curcumin reduced progression from prediabetes to type 2 diabetes, but HOMA-β remained an indirect endpoint. Salidroside has direct MIN6 and isolated-islet evidence supporting AMPK-dependent preservation of β-cell function, whereas ashwagandha is supported mainly by pancreatic findings in diabetic animals and by systemic metabolic or neuroendocrine outcomes. PI3K/Akt-, Nrf2-, NF-κB-, JNK-, UPR-, and incretin-related mechanisms have been reported, but their confirmation in β-cells is uneven and often derives from non-pancreatic models. Evidence for prevention of β-cell dedifferentiation, clinically relevant DPP-IV inhibition, and synergistic adaptogen combinations remains limited or hypothetical. Overall, these phytochemicals provide biological plausibility as adjunctive strategies, but standardized extracts, clinically achievable dosing, pharmacokinetic assessment, and β-cell-centered clinical endpoints are required before therapeutic conclusions can be established.
Insights
Four adaptogenic herbs show preclinical promise for protecting pancreatic beta-cells from damage. Further research is needed to confirm their therapeutic potential in humans for diabetes management.
Area of Science:
- Endocrinology and Metabolic Diseases
- Pharmacology and Herbal Medicine
- Cell Biology
Background:
- Pancreatic beta-cells are crucial for glucose homeostasis but vulnerable to various stressors.
- Glucotoxicity, lipotoxicity, oxidative stress, and inflammation impair beta-cell function and survival.
- Natural compounds are explored for their potential to protect beta-cells and manage diabetes.
Purpose of the Study:
- To review evidence for Panax ginseng, Curcuma longa (curcumin), Withania somnifera (ashwagandha), and Rhodiola rosea (salidroside) in modulating beta-cell function.
- To critically evaluate mechanistic, preclinical, and translational data on these phytochemicals.
- To identify key pathways and limitations for future research and clinical application.
Main Methods:
- Narrative review of studies from PubMed, Scopus, Web of Science, and Google Scholar.
- Prioritized studies using beta-cell lines, isolated islets, pancreatic tissue, and diabetic animal models.
- Included studies reporting clinical outcomes related to glycemic control and beta-cell function.
Main Results:
- Panax ginseng demonstrated islet preservation and endocrine-cell remodeling.
- Curcumin showed strong cytoprotection but faces bioavailability challenges; a trial suggested reduced prediabetes progression.
- Salidroside provided evidence for AMPK-dependent beta-cell function preservation; ashwagandha showed benefits mainly in animal models.
Conclusions:
- Phytochemicals like ginseng, curcumin, salidroside, and ashwagandha offer biological plausibility as adjunctive diabetes therapies.
- Current evidence is predominantly preclinical, with limitations in bioavailability, dosing, and beta-cell-specific clinical endpoints.
- Standardized extracts, pharmacokinetic studies, and beta-cell-focused trials are essential to establish therapeutic value.
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Type II Diabetes II: Pathophysiology
